Manage Account
Change Password
Sign Out
Gastrointestinal Stromal Tumor (GIST): SUTENT is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.
Advanced Renal Cell Carcinoma (RCC): SUTENT is indicated for the treatment of advanced renal cell carcinoma.
Pancreatic Neuroendocrine Tumour (pNET): SUTENT is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.
